Cost-Effectiveness of Novel TB Vaccines: A Modeling Study
2023
A modeling study assessed future costs, cost-savings, and cost-effectiveness of introducing novel tuberculosis (TB) vaccines in 105 low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies, compared to a ‘no-new-vaccine’ counterfactual. Vaccine scenarios considered two vaccine product profiles (one targeted at infants, one at adolescents/adults), both assumed to prevent progression to active TB. Vaccine introduction was estimated to require substantial near-term resources, offset by future cost-savings from averted TB burden. Across the analysis, TB vaccination would be highly impactful and cost-effective in most LMICs, and in some cases cost-saving.
Cost-Effectiveness of Novel TB Vaccines: A Modeling Study
Source:
Portnoy A, Clark RA, Quaife M et al. The Cost and Cost-Effectiveness of Novel Tuberculosis Vaccines in Low- and Middle-Income Countries: A Modelling Study. PLOS Medicine 2023; 20 (1). https://doi.org/10.1371/journal.pmed.1004155